EW vs ABT vs DXCM Stock Comparison

Edwards Lifesciences, Abbott Laboratories and Dexcom Prices as of Nov 13, 2026 Peers: Industry group
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$61.96B
P/E
61.1x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
4 wins
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$190.32B
P/E
40.5x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
2 wins
DXCM Dexcom Inc
$83.33 -0.2% 1M +39.5% 1Y
Market cap
$30.88B
P/E
31.2x
Revenue (TTM)
$5.10B
Div. yield
–
Medical Devices Healthcare
5 wins

Head to Head

11 decided of 12

Dexcom leads on 5 of the 12 questions below (Dexcom 5, Edwards Lifesciences 4, Abbott Laboratories 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionEWABTDXCMLeader
Larger companyMarket capitalisation $61.96B $190.32B $30.88B ABT
Cheaper on earningsLower P/E, profitable companies only 61.1x 40.5x 31.2x DXCM
Cheaper on forward earningsLower price / next fiscal year consensus EPS 37.6x 19.1x 29.1x ABT
Faster revenue growthRevenue growth, trailing twelve months +13.4% +10.0% +13.0% EW
More profitableNet margin, trailing twelve months 15.2% 9.7% 19.4% DXCM
Better return on capitalReturn on invested capital 8.7% 5.7% 32.4% DXCM
Less leveragedLower net debt / EBITDA -2.5x 2.5x -0.9x EW
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months +24.5% -16.0% +39.5% DXCM
Better 5-year returnAnnualised price return, 5 years -1.6%/yr -3.3%/yr -12.4%/yr EW
Less volatileAnnualised volatility, 1 year 25.5% 28.5% 37.9% EW
Higher overall scoreMean of the five percentile scores vs peers 77/100 56/100 80/100 DXCM

Percentile Scorecard

EWABTDXCM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisEWABTDXCM
Valuation 61 #96 of 243 74 #65 of 243 67 #82 of 243
Growth 57 #99 of 228 26 #168 of 228 83 #40 of 228
Profitability 96 #10 of 222 82 #41 of 222 100 #1 of 222
Financial Health 87 #34 of 248 33 #167 of 248 59 #103 of 248
Shareholder Returns 84 #26 of 158 65 #56 of 158 91 #15 of 158
Overall 77 56 80
  • EW ranked among 252 companies in Medical Devices and Diagnostics
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • DXCM ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodEWABTDXCMSPY
1 month +24.0%+5.4%-0.2% -2.0%
3 months +17.0%-2.4%-7.2% -2.8%
6 months +31.7%+28.5%+35.2% +2.0%
Year to date +25.7%-13.4%+25.6% +10.6%
1 year +24.5%-16.0%+39.5% +12.2%
3 years +62.9%+11.8%-17.8% +68.1%
3 years, per year +17.7%+3.8%-6.3% +18.9%
5 years -7.6%-15.5%-48.4% +61.4%
5 years, per year -1.6%-3.3%-12.4% +10.1%
10 years +253.3%+170.4%+411.2% +248.5%
10 years, per year +13.5%+10.5%+17.7% +13.3%

Risk

MeasureEWABTDXCMSPY
Volatility, 1Y 25.5%28.5%37.9% 13.6%
Downside volatility, 1Y 24.7%27.8%34.3% 13.9%
Beta vs S&P 500, 1Y 0.580.070.72 1.00
Return / volatility, 1Y 0.96-0.561.04 0.90
Max drawdown, 5Y -54.3%-41.6%-66.3% -25.4%
From 52-week high 0.0%-16.9%-9.8% -3.2%
52-week high $107.18$130.59$92.34 $779.14
52-week low $75.87$82.56$57.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleEWABTDXCM
P/E now vs peer median 60.9xmedian 26.5x 40.0xmedian 26.5x 31.5xmedian 26.5x
P/S now vs peer median 9.2xmedian 2.7x 3.9xmedian 2.7x 6.1xmedian 2.7x
EV/EBITDA now vs peer median 35.8xmedian 18.4x 20.3xmedian 18.4x 19.7xmedian 18.4x
P/FCF now vs peer median 43.3xmedian 25.4x 27.8xmedian 25.4x 28.3xmedian 25.4x
P/B now vs peer median 5.6xmedian 2.5x 3.6xmedian 2.5x 12.3xmedian 2.5x
PEG now vs peer median -6.65median 0.98 -13.92median 0.98 0.73median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsEWABTDXCM
Revenue $6.67B $48.23B $5.10B
Gross profit $5.21B $27.46B $3.24B
Operating income $1.44B $6.65B $1.22B
Net income $1.02B $4.70B $991.00M
Free cash flow $1.42B $6.76B $1.10B
R&D $1.09B $3.31B $608.10M
EPS (diluted) $1.76 $2.70 $2.58
Cash & equivalents $3.11B $4.05B $961.40M
Total debt $598.80M $31.16B $389.80M
Shares (diluted) 577.60M 1.74B 383.50M
Enterprise value $45.17B $164.19B $22.70B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricEWABTDXCM
P/E 60.9x 40.0x 31.5x
P/FCF 43.3x 27.8x 28.3x
P/Operating cash flow 35.9x 21.2x 22.0x
P/S 9.2x 3.9x 6.1x
P/B 5.6x 3.6x 12.3x
P/Tangible book 6.3x 5.9x 12.7x
EV/EBITDA 35.8x 20.3x 19.7x
EV/EBIT 40.0x 32.3x 24.2x
EV/Revenue 8.6x 4.5x 5.8x
EV/FCF 40.5x 31.8x 27.0x
EV/Operating cash flow 33.6x 24.3x 21.0x
PEG (3Y EPS CAGR) -6.65 -13.92 0.73

Growth

14 metrics
MetricEWABTDXCM
Revenue growth (1Y) 13.4% 10.0% 13.0%
Revenue CAGR (3Y) 16.9% 6.5% 14.5%
Gross profit growth (1Y) 13.2% 12.1% 21.5%
Gross profit CAGR (3Y) 13.7% 7.8% 14.2%
Operating income growth (1Y) 1.1% -13.8% 57.4%
Operating income CAGR (3Y) 5.8% 3.5% 34.2%
Net income growth (1Y) -25.2% -66.4% 37.5%
Net income CAGR (3Y) -10.6% -3.1% 38.0%
EPS growth (1Y) -24.5% -66.1% 46.1%
EPS CAGR (3Y) -9.2% -2.9% 43.0%
Operating cash flow growth (1Y) 68.9% -2.9% -2.3%
Operating cash flow CAGR (3Y) 18.1% 10.6% 23.7%
Free cash flow growth (1Y) 77.1% -2.3% 3.4%
Free cash flow CAGR (3Y) 20.8% 14.6% 30.0%

Profitability

14 metrics
MetricEWABTDXCM
Gross margin 78.0% 56.9% 63.4%
EBITDA margin 24.2% 21.9% 29.5%
Operating margin 21.6% 13.8% 24.0%
Pretax margin 21.5% 13.6% 24.7%
Net margin 15.2% 9.7% 19.4%
FCF margin 21.3% 14.0% 21.5%
Operating cash flow margin 25.7% 18.4% 27.7%
Return on equity 9.4% 9.1% 38.4%
Return on assets 7.2% 4.3% 15.6%
Return on invested capital 8.7% 5.7% 32.4%
Return on capital employed 11.6% 7.2% 29.9%
Asset turnover 0.5x 0.4x 0.8x
Cash conversion (OCF / net income) 1.7x 1.9x 1.4x
Stock comp / revenue 2.6% 1.5% 3.0%

Financial Health

11 metrics
MetricEWABTDXCM
Debt / assets 4.2% 28.8% 6.2%
Debt / equity 0.1x 0.6x 0.2x
Net debt / EBITDA -2.5x 2.5x -0.9x
Debt / FCF 0.4x 4.6x 0.4x
Liabilities / assets 22.5% 52.3% 59.4%
Equity / assets 77.5% 47.7% 40.6%
Interest coverage – 6.7x –
Current ratio 4.6x 1.5x 1.7x
Quick ratio 3.5x 0.8x 1.3x
Cash ratio 2.9x 0.3x 0.8x
Altman Z-score 14.42 3.36 7.53

Shareholder Returns

7 metrics
MetricEWABTDXCM
Dividend yield – 2.3% –
Net buyback yield 0.9% 0.7% 2.2%
Shareholder yield 0.9% 3.0% 2.2%
Payout ratio (earnings) – 92.0% –
Payout ratio (FCF) – 64.0% –
Dividend growth (1Y) – 6.9% –
Dividend CAGR (3Y) – 7.4% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusEWABTDXCM
Forward P/E 37.6xFY2026 19.1xFY2026 29.1xFY2026
EPS, next fiscal year $2.85FY2026 $5.69FY2026 $2.86FY2026
EPS growth, next FY +11.3%FY2026 +10.5%FY2026 +36.8%FY2026
EPS growth, the year after +12.6% +10.2% +4.2%
Revenue, next fiscal year $7.28BFY2026 $52.99BFY2026 $5.08BFY2026
Revenue growth, next FY +19.9%FY2026 +19.5%FY2026 +9.0%FY2026
Revenue growth, the year after -2.2% -2.3% +16.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersEWABTDXCM
Held by institutions 90.6% 79.2% 100.0%
Institutions holding 1,326 2,983 977
Change in shares held, QoQ +20.4% +0.3% +6.3%
Institutions buying 641 1,261 521
Institutions selling 456 1,379 345
Buyers to sellers 1.41 0.91 1.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

EWABTDXCM
EW 1.00 0.32 0.34
ABT 0.32 1.00 0.36
DXCM 0.34 0.36 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, EW, ABT and DXCM?

Abbott Laboratories (ABT) is the largest by market capitalisation: Edwards Lifesciences (EW) $61.96B, Abbott Laboratories (ABT) $190.32B, Dexcom (DXCM) $30.88B.

Which stock is cheaper, EW, ABT and DXCM?

Dexcom (DXCM) trades on the lowest price-to-earnings ratio (Edwards Lifesciences (EW) 61.1x, Abbott Laboratories (ABT) 40.5x, Dexcom (DXCM) 31.2x). On next year's consensus earnings, Abbott Laboratories (ABT) is cheapest (Edwards Lifesciences (EW) 37.6x, Abbott Laboratories (ABT) 19.1x, Dexcom (DXCM) 29.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Edwards Lifesciences (EW) +13.4%, Abbott Laboratories (ABT) +10.0%, Dexcom (DXCM) +13.0%.

Which company is more profitable?

Dexcom (DXCM) has the highest net margin (Edwards Lifesciences (EW) 15.2%, Abbott Laboratories (ABT) 9.7%, Dexcom (DXCM) 19.4%). On return on invested capital, Dexcom (DXCM) leads (Edwards Lifesciences (EW) 8.7%, Abbott Laboratories (ABT) 5.7%, Dexcom (DXCM) 32.4%).

Which stock has performed better?

Over the past year Dexcom (DXCM) returned the most: Edwards Lifesciences (EW) +24.5%, Abbott Laboratories (ABT) -16.0%, Dexcom (DXCM) +39.5%. Over five years, Edwards Lifesciences (EW) compounded fastest (Edwards Lifesciences (EW) -1.6%/yr, Abbott Laboratories (ABT) -3.3%/yr, Dexcom (DXCM) -12.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Edwards Lifesciences (EW) 0.00%, Abbott Laboratories (ABT) 0.02%, Dexcom (DXCM) 0.00%. Edwards Lifesciences (EW) and Dexcom (DXCM) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Edwards Lifesciences (EW) has been the steadiest (Edwards Lifesciences (EW) 25.5%, Abbott Laboratories (ABT) 28.5%, Dexcom (DXCM) 37.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, EW, ABT and DXCM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Dexcom (DXCM) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.